Latest news with #MUSC
Newsweek
5 days ago
- Health
- Newsweek
Map Shows States With Most HPV-Related Cancers as 1 in 3 Unaware of Link
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. People in some U.S. states are more likely to be diagnosed with HPV-associated cancers than in others—with this discrepancy likely linked to awareness of the risk from the virus. Overall, one in three adults nationally are unaware of the connection between HPV and cancer, reveals a study from the MUSC Hollings Cancer Center in South Carolina. HPV, or the human papillomavirus, is spread by skin-to-skin contact and has been linked to the onset of six different types of cancer. It is responsible for almost all cases of cervical cancers, causes the majority of throat or 'oropharyngeal' cancers and can cause anal, penile, vaginal and vulvar cancers. "Awareness of HPV in the general population is an important determinant of preventative care uptake," MUSC researcher Kalyani Sonawane told Newsweek. Such measures, she explained, include the HPV vaccine and cervical cancers screening. "Achieving adequate HPV vaccine coverage is critical for eliminating these cancers." State-level data from the Centers for Disease Control and Prevention (CDC)—see map above—shows geographical differences in the diagnoses of HPV-associated cancers. At joint top of the list, Kentucky and West Virginia recorded 16.9 HPV-associated cancer cases per 100,000 residents in 2022 (the year with the most recent available data.) However, at the bottom of the list, North Dakota recorded just 8.3 HPV-associated cancer cases per 100,000 residents in the same year. According to the new study, around a third of Americans are not aware of either HPV or that a vaccine exists against it—despite this protection having been available for nearly two decades in the U.S. This lack of awareness is heightened in the Midwest and South, the researchers noted. For example, more than 40 percent of people in 13 states—including South Carolina—are unaware there is a vaccine against HPV. "In general, literacy levels (overall and health literacy) are lower in the U.S. South and Midwest, which is likely a reason why we found a lack of HPV awareness concentrated in states in these regions," explained Sonawane. The team used data from the Health Information National Trends Survey (HINTS), a survey conducted by the National Cancer Institute, to inform their research. Sonawane said that the CDC data "further highlights the need for increasing HPV awareness in Southern and Midwestern states"—where cases of HPV-related cancer also tend to be more common. The vaccine is the "first and best defense" against HPV-caused cancers, the researchers said. It is routinely recommended for children aged 11–12 years (and can be started as early as nine years). Catch-up vaccination is recommended through age 26. Additionally, adults aged 27–45 might be able to receive the vaccine after consultation with their healthcare provider. Doctor examining throat of male patient. Doctor examining throat of male research from Europe and the U.S. shows a significant reduction in cervical cancer cases in young women—likely due to them being the first group to have been vaccinated as children—there's a bigger picture to consider. Cervical cancer may show up when people are in their 30s or 40s, but oropharyngeal cancers are mostly diagnosed when people are in their 50s or 60s, the researchers warn. Sonawane noted that the biggest knowledge gap is in relation to oropharyngeal cancer. Across the nation, 70 percent of those who have heard about HPV did not know that it can lead to throat cancer. The vaccine is now approved for boys too, but their vaccination rates remain lower than among girls. "The HPV vaccine was first approved for the prevention of cervical cancer in women and was therefore heavily marketed toward women. This 'feminization' of the HPV vaccine continues to linger—and is likely a reason why most people have heard of HPV and cervical cancer, but not of its link with oral cancers," Sonawane explained. "Boys and men can also get HPV-associated oral, penile, and anal cancers; therefore, getting the HPV vaccine is equally important for males." While the pandemic interrupted measures of preventive care—including the HPV vaccination and screening for breast, cervical and colon cancers—an American Cancer Society report showed screening for breast and colon cancers has since rebounded. However, both cervical cancer screening—which is not a test for cancer, but a test to help prevent cancer—and HPV vaccination rates have not similarly recovered. "Prevention is always better than a cure. We have a safe and effective vaccine to prevent six cancers," Sonawane said. She concluded: "Going forward, we need to ensure that every child and eligible adult is protected from HPV-related cancers by ensuring they are offered the opportunity—i.e., the HPV vaccine—for preventing these cancers." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about HPV? Let us know via health@ Reference Garg, A., Damgacioglu, H., Graboyes, E. M., Seal, S., Deshmukh, A. A., & Sonawane, K. (2025). State-level public awareness of HPV, HPV vaccine, and association with cancer. JAMA Oncology. Star, J., Han, X., Smith, R. A., Schafer, E. J., Jemal, A., & Bandi, P. (2025). Cancer Screening 3 Years After the Onset of the COVID-19 Pandemic. JAMA, 333(17), 1543–1546.
Business Wire
29-07-2025
- Business
- Business Wire
Saltgrass Advisory Launches to Power the Next Wave of Healthcare AI Innovation
CHARLESTON, S.C.--(BUSINESS WIRE)--Saltgrass Advisory, a strategic management consulting firm focused on artificial intelligence and emerging healthcare technologies, today announced its official launch. The firm partners with healthcare institutions, startups, and investors to accelerate high-impact innovation by turning cutting-edge capabilities into scalable, real-world solutions. 'Saltgrass Advisory brought the strategic insight and healthcare expertise we needed to define and commercialize our oncology AI innovation,' said Brett Berman, director of operations - health solutions, Medical University of South Carolina. Saltgrass Advisory is led by seasoned executives who bring a rare blend of healthcare, data, and AI expertise. Robert Goodman leverages his track record as a data & AI leader at Deloitte and as an executive within Blackstone-and Vista-backed technology companies. Brian Litten draws on decades as a healthcare operator, including a successful NASDAQ IPO with Tabula Rasa in 2016, his roles as CEO of PathForward Oncology and Swift Medical, and deep leadership experience across the Blue Cross network. Together they're positioning Saltgrass as a trusted partner to drive healthcare innovation at scale. With AI evolving rapidly—and healthcare organizations under growing pressure to deliver better outcomes at lower cost—Saltgrass Advisory enters the market at a pivotal time. The firm guides leaders through this transformation with a focus on intelligent infrastructure, clinical relevance, and operational execution. Impact in Action Saltgrass Advisory is already delivering measurable impact, recently guiding the Medical University of South Carolina (MUSC) on the commercialization of its oncology AI platform, LAMPER, which has driven: an 80% reduction in support staff burden per patient, a 10–20% increase in clinical trial accrual, and 3–4 hours saved per patient across roles. Time-to-appointment readiness has dropped from 1–2 days to under a day. In just one department at MUSC, LAMPER is projected to deliver $2.1M–$10.2M in cost savings over five years, while unlocking new revenue through increased patient throughput and clinical trial enrollment. 'Saltgrass Advisory brought the strategic insight and healthcare expertise we needed to define and commercialize our oncology AI innovation,' said Brett Berman, director of operations, MUSC Health. 'Their team translated academic discovery into real-world impact.' Focused Expertise at the Intersection of Strategy, Technology, and Delivery Saltgrass Advisory—powered by a leadership team of seasoned operators who've built, scaled, and exited companies across the healthcare ecosystem—helps clients accelerate outcomes and unlock healthcare value: Commercialization and go-to-market execution AI strategy, data platforms, intelligent models, seamless integrations, and scalable operations Fractional leadership across product, operations, technology, and growth 1:1 advisory for institutional leaders and startup founders Regulatory, compliance, and policy navigation The Saltgrass Team Brian Litten, Managing Partner – Former digital health founder & CEO Robert Goodman, Managing Partner – Former data & AI executive at Deloitte Lisa Davis, Principal– Past CIO of top U.S. health plan; Former SVP, Intel Health Solutions Munish Khaneja, MD, Principal – Former health plan CMO, EmblemHealth and HealthEdge Drew Narayan, Principal – Former strategy leader at Blue Cross Blue Shield of North Carolina Archana Puthran, Principal – Former AI & digital health leader at UnitedHealth, OptumRx Jacob Jesson, Principal – Former EVP & chief revenue and experience officer, Medecision Paige Bagby – Principal - Former Ogilvy communications and public relations leader Speaker Series Saltgrass Advisory is live, and so is its new speaker series highlighting concrete steps to scale health AI. The series debuts August 19 at 11 a.m. ET. Register here. About Saltgrass Advisory
National Post
29-07-2025
- Business
- National Post
Saltgrass Advisory Launches to Power the Next Wave of Healthcare AI Innovation
Article content CHARLESTON, S.C. — Saltgrass Advisory, a strategic management consulting firm focused on artificial intelligence and emerging healthcare technologies, today announced its official launch. The firm partners with healthcare institutions, startups, and investors to accelerate high-impact innovation by turning cutting-edge capabilities into scalable, real-world solutions. Article content Saltgrass Advisory is led by seasoned executives who bring a rare blend of healthcare, data, and AI expertise. Robert Goodman leverages his track record as a data & AI leader at Deloitte and as an executive within Blackstone-and Vista-backed technology companies. Brian Litten draws on decades as a healthcare operator, including a successful NASDAQ IPO with Tabula Rasa in 2016, his roles as CEO of PathForward Oncology and Swift Medical, and deep leadership experience across the Blue Cross network. Together they're positioning Saltgrass as a trusted partner to drive healthcare innovation at scale. Article content Article content With AI evolving rapidly—and healthcare organizations under growing pressure to deliver better outcomes at lower cost—Saltgrass Advisory enters the market at a pivotal time. The firm guides leaders through this transformation with a focus on intelligent infrastructure, clinical relevance, and operational execution. Article content Impact in Action Article content Saltgrass Advisory is already delivering measurable impact, recently guiding the Medical University of South Carolina (MUSC) on the commercialization of its oncology AI platform, LAMPER, which has driven: an 80% reduction in support staff burden per patient, a 10–20% increase in clinical trial accrual, and 3–4 hours saved per patient across roles. Time-to-appointment readiness has dropped from 1–2 days to under a day. In just one department at MUSC, LAMPER is projected to deliver $2.1M–$10.2M in cost savings over five years, while unlocking new revenue through increased patient throughput and clinical trial enrollment. Article content 'Saltgrass Advisory brought the strategic insight and healthcare expertise we needed to define and commercialize our oncology AI innovation,' said Brett Berman, director of operations, MUSC Health. 'Their team translated academic discovery into real-world impact.' Article content Focused Expertise at the Intersection of Strategy, Technology, and Delivery Article content Saltgrass Advisory—powered by a leadership team of seasoned operators who've built, scaled, and exited companies across the healthcare ecosystem—helps clients accelerate outcomes and unlock healthcare value: Article content Commercialization and go-to-market execution AI strategy, data platforms, intelligent models, seamless integrations, and scalable operations Fractional leadership across product, operations, technology, and growth 1:1 advisory for institutional leaders and startup founders Regulatory, compliance, and policy navigation Article content The Saltgrass Team Article content Brian Litten, Managing Partner – Former digital health founder & CEO Robert Goodman, Managing Partner – Former data & AI executive at Deloitte Lisa Davis, Principal– Past CIO of top U.S. health plan; Former SVP, Intel Health Solutions Munish Khaneja, MD, Principal – Former health plan CMO, EmblemHealth and HealthEdge Drew Narayan, Principal – Former strategy leader at Blue Cross Blue Shield of North Carolina Archana Puthran, Principal – Former AI & digital health leader at UnitedHealth, OptumRx Jacob Jesson, Principal – Former EVP & chief revenue and experience officer, Medecision Paige Bagby – Principal – Former Ogilvy communications and public relations leader Article content Speaker Series Article content Saltgrass Advisory is live, and so is its new speaker series highlighting concrete steps to scale health AI. The series debuts August 19 at 11 a.m. ET. Register here. About Saltgrass Advisory Part of the Saltgrass Companies ecosystem, Saltgrass Advisory operates in lockstep with Saltgrass Capital, Saltgrass Venture Studios, and Saltgrass Institute to accelerate the future of healthcare. Together, these firms bring clarity, speed, and execution power—transforming AI visions into real-world impact. Follow our updates on LinkedIn. For more information, visit or contact . Article content Article content Article content Article content
Yahoo
10-07-2025
- Business
- Yahoo
Fidelity National Information (FIS) Partners with MUFG Securities
Fidelity National Information Services, Inc. (NYSE:FIS) is one of the 10 Most Undervalued Technology Stocks to Buy Right Now. On May 28, Fidelity National Information Services, Inc. (NYSE:FIS) announced a new partnership with MUFG Securities (Canada), Ltd. MUFG is a broker-dealer serving institutional clients in the Canadian capital markets. Under the partnership, MUSC has chosen FIS' Post Trade Processing Platform to handle its back-office operations. The platform will help MUSC streamline its processes by making trade settlements, confirmations, and accounting faster and more reliable. Notably, the system operates in real time, thereby reducing delays and errors. A financial analyst monitoring the stock market, with multiple screens of varying sizes and colors. Fidelity National Information Services, Inc. (NYSE:FIS) noted that broker-dealers face many challenges today, including tougher regulations, higher technology costs, new competitors, and shrinking profit margins. The platform helps address these issues by automating and simplifying workflows. Fidelity National Information Services, Inc. (NYSE:FIS) is an international financial technology company that provides platforms and solutions for businesses and financial institutions. While we acknowledge the potential of FIS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. 登入存取你的投資組合
Yahoo
16-06-2025
- Health
- Yahoo
MUSC receives historic $50 million anonymous gift to transform health care, medical education in South Carolina
Charleston, SC, June 16, 2025 (GLOBE NEWSWIRE) -- The Medical University of South Carolina (MUSC) College of Medicine has received a landmark $50 million anonymous donation—the largest single gift in MUSC's 200-year history. This transformational investment will accelerate MUSC's mission to help people live longer, healthier lives and address South Carolina's most pressing health challenges. The unprecedented gift comes at a pivotal time, as South Carolina faces some of the nation's most challenging health outcomes and a rapidly aging population. The funds will support the College of Medicine's commitment to innovative medical education and enable expansion of opportunities to train more physicians at a time when our state is facing a significant shortage in health care providers. The donation will also enable MUSC to attract, train and retain the most gifted physicians, renowned faculty and researchers, positively impacting the lives of students, patients and families. 'For two centuries, MUSC has been an innovative health care leader in South Carolina. Yet, with growing chronic disease rates the need for bold action has never been greater. This extraordinary act of generosity will empower us to lean into the next century as we reimagine medical education, drive innovation and dramatically improve health outcomes for all South Carolinians,' said David J. Cole, M.D., FACS, president of MUSC. 'This gift is a testament to the power of partnership and the belief that together we can change the future of health in South Carolina,' said Terrence E. Steyer, M.D., dean of the College of Medicine and vice president for Medical Affairs. 'It will allow us to provide a world-class learning environment for our students and faculty and fuel groundbreaking research and clinical programs that will benefit patients across the state and beyond.' As part of this vision, a new home for the College of Medicine is currently under construction and will serve as a hub for collaboration, discovery and innovation, supporting the education of future physicians and the advancement of life-saving treatments. 'This is more than a gift—it's an investment in the health and well-being of our entire state,' said MUSC Board of Trustees Chairman Charles W. Schulze. 'We are deeply grateful for the vision and commitment of these donors, which will enable us to build a healthier future for South Carolina.' MUSC is committed to honoring the donors, who wish to remain anonymous, while ensuring that their legacy will be felt by countless individuals and families for years to come. ### About MUSC Founded in 1824 in Charleston, MUSC is the state's only comprehensive academic health system, with a mission to preserve and optimize human life in South Carolina through education, research and patient care. Each year, MUSC educates over 3,100 students in six colleges and trains 950+ residents and fellows across its health system. MUSC leads the state in federal and National Institutes of Health and research funding. For information on our academic programs, visit As the health care system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest-quality and safest patient care while educating and training generations of outstanding health care providers and leaders to serve the people of South Carolina and beyond. In 2024, for the 10th consecutive year, U.S. News & World Report named MUSC Health University Medical Center in Charleston the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit MUSC has a total enterprise annual operating budget of $7.1 billion. The 31,000 MUSC members include world-class faculty, physicians, specialty providers, scientists, contract employees, affiliates and care team members who deliver groundbreaking education, research and patient care. CONTACT: Staci Gouveia The Medical University of South Carolina 854-202-0907 mediarelations@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
